Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

Eligible patients were investigator - determined surgical candidates with resectable stage II-IIIB NSCLC, negative PD-L1 expression, no evidence of distant metastasis , and no evidence of unresectable localized tumor extension. This study plans to enroll 54 patients.Patients are scheduled to receive one preoperative dose of sintilimab plus IBI310 combined with chemotherapy and three doses of sintilimab combined with chemotherapy as neoadjuvant therapy. Surgery will be performed on patients deemed operable by the investigator at least 3 weeks after the last dose of study drug. Following surgery, the investigator will assess the patient's response. Postoperatively, patients may continue receiving standard adjuvant therapy with PD-1 inhibitor for one year.